Adefovir dipivoxil in hepatitis B patients infected with different HBV genotypes
Genotypic substudy of 698 serum samples from patients enrolled in Studies 437 and 438.
HBV genotypes were determined for all base line serum samples and the activity of adefovir dipivoxil was analyzed against all seven HBV genotypes (A-F).
After 48 weeks, treatment with adefovir dipivoxil resulted in significant decrease in serum HBV DNA across all HBV genotypes (mean reductions ranging from 3.4 to 4.2 log10 copies per ml).